STOCK TITAN

Mangoceuticals, Inc. - MGRX STOCK NEWS

Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.

Mangoceuticals, Inc. (NASDAQ: MGRX) is a dynamic company focusing on the development, marketing, and sale of men's wellness products and services. Specializing in telemedicine, Mangoceuticals provides a convenient platform for men to access essential healthcare. Through this platform, customers can connect with licensed pharmacies to obtain medications prescribed during telehealth consultations. One of the flagship offerings includes Mango ED products, which have gained significant attention for their effectiveness and ease of access.

In recent achievements, Mangoceuticals has expanded its portfolio to include a wider range of wellness products, continually enhancing user experience and accessibility. The company’s ongoing projects focus on integrating advanced telemedicine technologies to streamline consultation and prescription processes. Financially, Mangoceuticals has shown promising growth, with strategic partnerships bolstering its market presence and operational capabilities.

Mangoceuticals is committed to providing quality healthcare solutions tailored to men's needs, ensuring privacy, convenience, and professional guidance at every stage. Investors and stakeholders can expect steady updates on the company's performance, new product launches, and strategic developments, making MGRX a noteworthy stock in the wellness and telemedicine sectors.

Rhea-AI Summary

MangoRx (NASDAQ: MGRX) has received a Certificate of Grant in India for its respiratory illness and preventive care technology patent. The patent, valid until March 16, 2040, covers a proprietary formulation designed to combat infections including colds, respiratory diseases, and orally transmitted infections like HPV. This follows MangoRx's acquisition of Intramont Technologies' global patent portfolio on April 24, 2024.

The technology uses an orally available solution containing GALALCOOL®️, zinc protoporphyrin IX, and select tannins to inhibit various pathogens. MangoRx and Intramont have initiated clinical trials in India to demonstrate the formulation's efficacy in preventing respiratory illnesses, with results expected later this quarter. The company is also considering expanding trials to address avian influenza concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

MangoRx (NASDAQ: MGRX) has successfully migrated to a DEA-approved telemedicine platform, marking a significant advancement in its capabilities. This new system allows MangoRx's third-party doctor network to prescribe controlled substances, including Prime by MangoRx, an Oral Testosterone Replacement Therapy. The platform has accelerated the company's timeline for introducing new product lines, particularly the Slim and Trim weight loss products featuring Semaglutide and Tirzepatide in oral dissolvable tablets.

The company expects to launch these products before the end of Q3, capitalizing on the high demand for GLP-1 weight loss treatments. MangoRx has also unveiled a redesigned website with improved UI/UX, optimized for enhanced customer workflows. The HIPAA-compliant system ensures regulatory compliance and data security, setting a new benchmark for excellence in telemedicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.86%
Tags
none
-
Rhea-AI Summary

MangoRx (NASDAQ:MGRX), a men's health telemedicine company, has received its first Request for Proposal (RFP) from the International Society of Frontier Life Sciences and Technology (ISFLST) for a new male enhancement product targeting the Asian market. The product will be manufactured in the USA using GMP-compliant facilities. A pilot program is planned for 50 retail locations in China, with potential expansion to 5,000 locations.

The company's participation in a Beijing exhibit was successful, leading to new distribution partnerships and media coverage. MangoRx plans to expand its presence with exhibits in Shanxi Province, Hangzhou, and Beijing. Additionally, the company's existing products, Mango and Grow, are under review for regulatory approval in Asian markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
Rhea-AI Summary

MangoRx (NASDAQ: MGRX) has initiated efficacy studies on its patented respiratory illness prevention technology. The studies, pre-funded and expected to conclude in early Q3, will be conducted in collaboration with Vipragen Biosciences and IntraMont Technologies. The technology aims to reduce the incidence of respiratory illnesses, including H1N1 variants, Avian Flu, common cold, and Coronavirus.

The composition being tested contains a select tannin (enhanced polyphenol) and zinc gluconate. Previous research at Moscow State University showed a 93% decrease in active virus compared to the control group. The product is anticipated to be available as a lozenge or toothpaste, targeting the global influenza market valued at $8.28 billion in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
none
-
Rhea-AI Summary

Mangoceuticals (NASDAQ: MGRX) CEO Jacob Cohen was recently featured on Benzinga All-Access, discussing the company's strategic direction and future plans. Cohen highlighted MangoRx's focus on developing and marketing men's health products in areas such as erectile dysfunction, hair growth, weight loss, and hormone replacement therapies.

During the interview, Cohen emphasized the company's commitment to innovation and excellence in the health and wellness industry. He also discussed recent developments, expanding product offerings, and plans for global expansion, particularly in emerging markets. Cohen expressed optimism about the significant growth opportunities within the health and wellness sector and MangoRx's position to capitalize on these opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Summary

MangoRx (NASDAQ: MGRX) has secured DEA approval for its proprietary HIPAA-compliant operating system via Surescripts, positioning the company at the forefront of the direct-to-consumer telemedicine market. This authorization allows MangoRx to prescribe controlled medications, including hormone replacement therapies, through the nation's leading health information network.

The approval is expected to drive significant growth by enabling the company to expand its offerings and hyperscale operations. MangoRx's new operating system, developed over nearly a year, aims to revolutionize patient management with features like seamless doctor visits, prescription auto-refills, and personalized healthcare solutions. The company anticipates exponential growth in its subscriber base following this milestone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.4%
Tags
none
Rhea-AI Summary

MangoRx has appointed Dr. Douglas Christianson, N.D. as Director of Medical Research and Product Innovation. Dr. Christianson will drive new product development, conduct market research, and analyze innovative healthcare treatments for men's health, including erectile dysfunction, hair growth, weight loss, and hormone replacement therapies. He will develop and certify custom compound formulations and medical protocols, and collaborate with nationwide doctors for onboarding and training. Dr. Christianson, a specialist in male optimization therapies and regenerative medicine, brings extensive experience and insight into current market trends and progressive medicine. His expertise will help MangoRx expand its product offerings and stay ahead of competitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
management
-
Rhea-AI Summary

MangoRx (NASDAQ: MGRX) has announced a strategic partnership with the International Society of Frontier Life Sciences and Technology (ISFLST) to expand its presence in China, Asia Pacific, and Latin America (excluding Mexico). This collaboration aims to enhance the visibility and adoption of MangoRx's men's health products, including erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, in these rapidly growing markets. ISFLST will leverage its network in the US, China, and South Korea to introduce MangoRx's products. CEO Jacob Cohen highlighted the substantial market opportunity, citing an estimated 400 million males aged 35 and above in China. Marketing activities have already begun in Beijing and Hangzhou, with further plans for South Korea and Southeast Asia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
partnership
-
Rhea-AI Summary

MangoRx, a developer of men's health products, announced that its Australian patent application for a new preventive care technology has been accepted. This follows a similar acceptance in Japan. The technology targets respiratory and orally transmitted infections using a formulation with GALALCOOL®️, zinc protoporphyrin IX, and tannins. This patent strengthens their global intellectual property portfolio, especially following MangoRx's recent acquisition of Intramont Technologies' patents. The official patent publication is set for June 6, 2024, with an anticipated deed issuance by September 6, 2024, barring any opposition. This move aligns with MangoRx’s mission to offer advanced health solutions worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
none
Rhea-AI Summary

MangoRx, a company specializing in men's health and wellness, has received a Notice of Allowance for its Japanese Patent Application No. 2021-545824. This patent, initially applied for by Intramont Technologies, covers a formulation designed to prevent oral and respiratory infections. The technology includes ingredients like GALALCOOL®️, zinc protoporphyrin IX, and tannins. This follows MangoRx's acquisition of Intramont's global patent portfolio, including U.S. Patent 11,517,523. The patent solidifies MangoRx's intellectual property and paves the way for introducing its products in Japan, aligning with its mission to offer advanced preventive care solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.01%
Tags

FAQ

What is the current stock price of Mangoceuticals (MGRX)?

The current stock price of Mangoceuticals (MGRX) is $2.48 as of December 23, 2024.

What is the market cap of Mangoceuticals (MGRX)?

The market cap of Mangoceuticals (MGRX) is approximately 6.0M.

What is Mangoceuticals, Inc.?

Mangoceuticals, Inc. is a company specializing in men's wellness products and services, primarily through a telemedicine platform.

What products does Mangoceuticals offer?

Mangoceuticals offers a range of men's wellness products, including Mango ED products, which are accessible via their telemedicine platform.

How does Mangoceuticals' telemedicine platform work?

The platform allows customers to consult with healthcare professionals online, who can then prescribe medications that are fulfilled and distributed by licensed pharmacies.

What recent achievements has Mangoceuticals made?

Mangoceuticals has expanded its product range and integrated advanced technologies to improve telehealth consultations and prescription processes.

What is the financial condition of Mangoceuticals?

Mangoceuticals has shown promising growth, supported by strategic partnerships that enhance its market presence and operational capabilities.

Who can benefit from Mangoceuticals' services?

Men looking for convenient and private access to wellness products and telehealth consultations can benefit from Mangoceuticals' services.

What is the significance of Mango ED products?

Mango ED products are notable for their effectiveness in treating erectile dysfunction, with the added convenience of being accessible online.

What makes Mangoceuticals noteworthy in the stock market?

Mangoceuticals is noteworthy for its innovative approach to men's wellness, strong growth potential, and commitment to expanding its product and service offerings.

How does Mangoceuticals ensure the privacy of its customers?

Mangoceuticals ensures privacy through secure telehealth consultations and discrete prescription fulfillment processes.

What should investors expect from Mangoceuticals in the future?

Investors can expect ongoing updates on performance, new product innovations, and strategic developments that may impact the company's market position.

Mangoceuticals, Inc.

Nasdaq:MGRX

MGRX Rankings

MGRX Stock Data

5.97M
1.74M
37.45%
4.69%
7.69%
Health Information Services
Services-misc Health & Allied Services, Nec
Link
United States of America
DALLAS